Lucius LuciBren Brensocatib 10mg

Product Information

• Product name: LuciBren Brensocatib10mg30 Brensocatib 10mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Brensocatib
• Current strength: 10mg
• SKU: Product ID 3116
• Site category: general medicines

Product Summary

LuciBren Brensocatib10mg30 Brensocatib 10mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Brensocatib is the active ingredient used for this product page. Public prescribing information for Brensocatib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Brensocatib is a competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow. Activated NSPs are implicated in the pathogenesis of neutrophil-mediated NCFB inflammation.

Reference Indications

Brensocatib is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. Brensocatib is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older.

Reference Dosage and Administration

Recommended dosage: 10 mg or 25 mg orally once daily with or without food.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Refer to the dental care services for regular dental checkups and advise patients to perform routine dental hygiene. Live Attenuated Vaccines : It is unknown whether administration of live attenuated vaccines during Brensocatib treatment will affect the safety or effectiveness of the vaccines. Avoid use of live attenuated vaccines. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings. Refer patients to dental care services for regular dental checkups while taking Brensocatib. Advise patients to perform routine dental hygiene. It is unknown whether administration of live attenuated vaccines during Brensocatib treatment will affect the safety or effectiveness of these vaccines.

Common Adverse Reactions and Monitoring

The safety data below reflect the safety of Brensocatib in adult and pediatric patients aged 12 years and older with non-cystic fibrosis bronchiectasis (NCFB). A total of 1721 patients with NCFB were randomized in a double-blind, placebo-controlled clinical trial of 52 weeks duration (ASPEN) . The safety of Brensocatib was based on data from 1719 adult and pediatric patients aged 12 years and older who received at least one dose of Brensocatib or placebo. A total of 1156 patients received at least one dose of Brensocatib 10 mg or 25 mg orally once daily.

Drug Interactions and Special Populations

Oral administration of brensocatib to pregnant rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to 20 times the MRHD. No adverse development effects were observed after oral administration of brensocatib to pregnant rats from the period of organogenesis through lactation at doses that produced maternal exposures 17 times the MRHD on an AUC basis (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Brinsupri public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.